디클로르페나미드

용도

• Adjunctive treatment of glaucoma
• Adjunctive treatment of glaucoma
• Adjunctive treatment of glaucoma
• Adjunctive treatment of glaucoma
• Adjunctive treatment of glaucoma

투여 방법

가능한 부작용

• Panting
• GI disturbances (inappetence, vomiting, diarrhea)
• CNS effects (sedation, depression, excitement)
• Hematologic effects (bone marrow depression)
• Renal effects (crystalluria, dysuria, renal colic, polyuria)
• Metabolic acidosis
• Hypokalemia
• Hyperglycemia
• Hyponatremia
• Hyperuricemia
• Hepatic insufficiency
• Dermatologic effects (rash)
• Hypersensitivity reactions

주의사항 및 금기

• Significant hepatic disease (may precipitate hepatic coma)
• Renal or adrenocortical insufficiency
• Hyponatremia
• Hypokalemia
• Hyperchloremic acidosis
• Electrolyte imbalance
• Severe pulmonary obstruction (unable to increase alveolar ventilation)
• Hypersensitivity to carbonic anhydrase inhibitors
• Chronic, noncongestive, angle-closure glaucoma (long-term use)
• > **Warning**: Long-term use is contraindicated in patients with chronic, noncongestive, angle-closure glaucoma as it may mask the condition by lowering IOP while angle closure progresses. * Use with extreme caution in patients with pre-existing electrolyte imbalances (especially hypokalemia or hyponatremia). * May precipitate hepatic coma in patients with severe liver disease. * Avoid in patients with severe pulmonary obstruction who cannot increase alveolar ventilation to compensate for metabolic acidosis. * **Pregnancy Category C**: Teratogenic effects observed in animal studies; use only if benefits outweigh risks. * **Laboratory Interference**: May cause false-positive results for urine protein using certain test methods (e.g., bromphenol blue, sulfosalicylic acid) due to urine alkalinization. May also decrease iodine uptake by the thyroid gland.

약물 상호작용

• Antidepressants, Tricyclic: Alkaline urine caused by dichlorphenamide may decrease excretion of tricyclic antidepressants.
• Aspirin (or other salicylates): Increased risk of dichlorphenamide accumulation and toxicity; increased risk for metabolic acidosis; dichlorphenamide increases salicylate excretion.
• Digoxin: Dichlorphenamide may cause hypokalemia, leading to an increased risk for digoxin toxicity.
• Insulin: Rarely, carbonic anhydrase inhibitors interfere with the hypoglycemic effects of insulin.
• Methenamine compounds: Dichlorphenamide may negate the effects of methenamine in the urine due to alkalinization.
• Potassium-depleting drugs (corticosteroids, amphotericin B, corticotropin, diuretics): Concomitant use may exacerbate potassium depletion.
• Phenobarbital: Increased urinary excretion, which may reduce phenobarbital levels.
• Primidone: Decreased primidone concentrations.
• Quinidine: Alkaline urine caused by dichlorphenamide may decrease quinidine excretion.

자주 묻는 질문